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with more severe nephritis, an induction course of immuno-
suppressive therapy is recommended—typically, intravenous
cyclophosphamide (IVC) or mycophenolate mofetil (MMF), fol-
lowed by a maintenance course, typically of azathioprine. The
objective is to determine which induction therapy results in
better quality of life for patients, and which represents best value
for money. METHODS: A patient-level simulation is used to
model the total costs and QALYs gained of a patient treated with
either IVC or MMF for an induction period of six months. Efﬁ-
cacy data are extracted from a systematic review of randomised
controlled trials, and utility, resource and unit cost data from
published sources and standard databases. The perspective and
setting of the model is the English NHS and the price year, 2005.
An incremental analysis demonstrates the relative cost-effective-
ness of the two options. RESULTS: On average, MMF is more
effective (resulting in improved quality of life) when compared
with IVC (mean 0.039 QALYs gained over six months). MMF
therapy is less expensive overall than IVC, on average ≤1600 less
over the period. Therefore, MMF dominates IVC. The major
determinant and cost driver of this result is the requirement for
a day-case procedure to administer IVC. Analysis of uncertainty
shows an 81% probability that MMF will be cost-effective 
compared with IVC at a willingness to pay of approximately
.21230,000 per QALY gained. CONCLUSION: Treatment with
MMF is likely to be more effective and less expensive overall
than IVC as induction therapy for LN.
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PANEL DATA ANALYSIS SHOWS PERITONEAL DIALYSIS TO 
BE NEGATIVELY ASSOCIATED WITH HOSPITALIZATION AT
THE STATE LEVEL
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OBJECTIVES: Hemodialysis (HD) and peritoneal dialysis (PD)
are the two main types of dialysis therapy performed on patients
with ESRD. The United States Renal Data System (USRDS) pro-
duces, among a host of other types of data, annual State-level
data related to dialysis and hospitalizations. Panel data sets
(cross-sectional time series) can be created from these USRDS
data to estimate the impact of dialysis therapy on hospitalization
rates at an aggregate level. The objective of this study is to assess
the relationship of hospitalizations and dialysis therapies using
USRDS State-level data. METHODS: Data used in the analysis
were obtained from the 1999 through 2005 Annual Data
Reports on the USRDS Web site. The data covers the ﬁfty states
plus Washington D.C. for the years 1997 through 2003. Regres-
sion analysis was performed on the panel data using the
TSCSREG procedure in SAS 9.1. A one-way ﬁxed effects model
was used. The dependent variable was the Standardized Hospi-
talization Ratio (SHR). SHR is the ratio of observed over
expected hospitalization events in the ESRD population. The
independent variables included in the regression analysis were
dialysis modality, demographics, and other State-level data.
RESULTS: The adjusted R2 for the estimated regression model
was 0.88. The results showed that the percent of dialysis patients
on PD was negatively associated with SHR (p < 0.01) whereas
HD was positively associated with SHR (p < 0.01). In addition,
an interaction term between the percent of the ESRD population
with diabetes and the percent of the State population under 65
years of age was positively associated with SHR (p < 0.0001).
CONCLUSION: A robust econometrics model on aggregate
State-level USRDS data showed PD was negatively associated
with hospitalization. Policymakers and payers need to carefully
consider the impact of health care policy on dialysis modality
choice and thus on costs.
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OBJECTIVES: Women with chronic kidney disease (CKD) are
often at risk of having anemia. This study examined the varia-
tion in anemia care of CKD among women in outpatient settings
in the U.S. METHODS: This cross-sectional study used data
from the National Ambulatory Medical Care Survey (NAMCS)
from 1996–2003. Women aged 18 years and older with CKD
were included in the study sample based on clinical diagnoses
and the reason for the visit. Anemia diagnoses were retrieved
using clinical diagnoses and anemia-related medications 
(Erythropoietic stimulating agents or iron replacement) were
retrieved using the NAMCS drug codes. All analyses were
weighted to make national estimates. RESULTS: There were
approximately 58 million weighted outpatient visits for women
with CKD in the outpatient settings from 1996 to 2003. Nearly
14% of these visits were related to Hispanics and 50% of these
visits were by patient aged 65 years and older. Nephrologists
accounted for only 15% of CKD patient visits and 58% of these
patients had a diagnosis of anemia. Only 11% of visits with
anemia resulted in prescription for anemia related medication
(erythropoietin stimulating agents or iron replacement). Women
with Medicare coverage were 2.6 times more likely (p ≤ 0.05) to
be seen by nephrologists. Women seen by nephrologists were 2.4
times more likely (p ≤ 0.05) to receive a prescription for an ery-
thropoietin stimulating agent compared to patients seen by non-
nephrologists. Additionally, PCPs were less likely (p ≤ 0.05) to
prescribe erythropoietin stimulating agents compared to non-
PCPs. CONCLUSION: The ﬁndings of this study suggest that
PCPs are less likely to prescribe anemia medications in US out-
patient settings compare to non-PCPs. Increased awareness of
the impact of early treatments of anemia among women with
CKD is needed in outpatient settings in the U.S.
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OBJECTIVES: To understand current real-world utilization of
erythropoietic agents, this study examined epoetin alfa (EPO)
and darbepoetin alfa (DARB) dosing patterns and treatment
costs in elderly patients with chronic kidney disease (CKD) not
receiving dialysis. METHODS: A retrospective analysis was con-
ducted using medical claims from approximately 35 health plans
nationwide during the period of January 2004 through Febru-
ary 2006. To be included in the analysis, patients were required
to be ≥65 years old, have ≥2 EPO or DARB claims, have a CKD
diagnosis within 90 days prior to EPO or DARB initiation, and
be newly initiated on either agent. If a patient received renal dial-
ysis, data were censored 30 days prior to the ﬁrst date of dialy-
sis. Patients diagnosed with cancer or that received
chemotherapy were excluded. Mean weekly doses weighted by
treatment duration were used to calculate drug costs based 
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on September 2006 wholesale acquisition costs (EPO:
$0.01217/Unit, DARB: $4.446/mcg). RESULTS: 439 patients
(296 EPO, 143 DARB) met the entry criteria and formed the
study population. The two groups of patients had similar mean
age (years; EPO 74.9 vs. DARB 74.3) and gender distribution
(female; EPO 51.0% vs. DARB 51.8%). Use of extended dosing
regimens (≥every two weeks [≥Q2W]) was observed in the
majority of patients in both groups (EPO: 71%; DARB: 92%).
The mean (SD) dose per injection was 25,987 (19,298) Units for
EPO and 114.9 (131.1) mcg for DARB. The weighted average
(SD) weekly dose was 13,879 (12,121) Units for EPO and 54.5
(50.2) mcg for DARB, corresponding to an average weekly ery-
thropoietic drug cost of $169 for EPO and $242 for DARB (P
< 0.0001). CONCLUSION: This retrospective claims analysis
reported use of extended dosing (≥Q2W) of both EPO and
DARB in CKD patients aged ≥65 years. Weekly DARB costs
were 43% higher than EPO.
URINARY/KIDNEY—Patient-Reported Outcomes
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OBJECTIVES: To estimate adherence with immunosuppressant
medications in transplant patients served by a group of ﬁve spe-
cialty pharmacies and to assess the medical cost avoidance asso-
ciated with improved adherence, where possible. METHODS:
Prescription ﬁll data were obtained from ﬁve specialty pharma-
cies for Medicare patients who had prescriptions ﬁlled from
January 2005 to June 2005 for one of the following medications:
azathioprine, mycophenolate mofetil, mycophenolic acid, and
sirolimus. Patients were eligible for analysis if they had a pre-
scription ﬁlled in both January and June. Medication possession
ratios (MPRs) were calculated for each medication over the study
period. Patients with MPRs > 0.8 were classiﬁed as adherent. Lit-
erature-based adherence estimates were obtained for compari-
son. The 2005 US Renal Data System Annual Data Report was
used to gather clinical and economic outcome data for a deci-
sion analysis to determine whether differences in adherence
resulted in potential cost avoidance associated with a rejected
renal graft. RESULTS: In the 1599 eligible patients, the estimated
adherence rate was 84.2%, which was signiﬁcantly higher than
the literature-based estimate of 65% (p < 0.01). After applying
the adherence estimates to current Medicare cost estimates for
functioning renal grafts and failed renal grafts, the estimated
yearly cost in study pharmacy patients was $27,853 versus
$32,003 using literature-based adherence estimates—a potential
cost savings of $4150 per patient per year. CONCLUSION:
These ﬁndings suggest that the reduced risk of rejection associ-
ated with increased adherence with immunosuppressant agents
translates into avoidance of signiﬁcant costs associated with
failed renal grafts. Compared to traditional mail-order or retail
pharmacies, the service model used by the study pharmacies
involves high levels of patient contact to promote adherence.
Policies to ensure appropriate reimbursement, such as CMS’s
proposed pay-for-performance framework, would be an impor-
tant step to support and promote optimal patient care.
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OBJECTIVES: Stress urinary incontinence (SUI) is a common
condition in women, caused by anatomical problems related to
factors such as age, parity, white race, hormonal state, higher
educational attainment, pregnancy related factor and higher
body mass index. Several studies indicate obesity as an impor-
tant SUI related factor. This study was conducted to investigate
the impact of obesity in the quality of life of women with urinary
incontinence. METHODS: Women with the symptom of SUI
were recruited prospectively over a 3-months period from a ter-
tiary referral urogynaecology center in a teaching hospital. A
group of 86 women complaining of SUI and conﬁrmed as having
SUI on urodynamic assessment agreed to participate. The King’s
Health Questionnaire (KHQ) was applied before any treatment
to assess the impact of SUI in the quality of life. We then divided
the patients in two groups, obese and non obese women, accord-
ing to their BMI (>30 BMI and <30 BMI) and compared them
using Student t test. RESULTS: There were 25 patients in the
obese group and 61 in the non obese group. There were no sta-
tistical differences between the groups concerning, age, number
of pregnancies, height and daytime frequency. The obese patient
group was heavier (p < 0.0000), with greater BMI (p < 0.0000)
with an also statistically greater nighttime frequency (p =
0.0147). The obese group had more time of SUI symptoms com-
plain (p = 0.0268). Of the evaluated domains of the KHQ
(general health perception, incontinence impact, role limitations,
physical limitations, social limitations, personal relationships,
emotions, sleep/energy, severity measures) only the severity mea-
sures were statistically different among these two groups (p =
0.0093). CONCLUSION: Obesity seems to aggravate the per-
ception of the severity of the urinary incontinence problem in
women.
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OBJECTIVES: The objective of this study was to evaluate the
linguistic validity of 10 translations of the Nocturia Quality of
Life (N-QOL) questionnaire. This self-administered question-
naire was originally developed in English (UK) to measure the
impact of nocturia on health-related quality of life in men with
lower urinary tract symptoms (LUTS), and has since been vali-
dated for use in women. METHODS: Harmonized translations
of the questionnaires were created through an internationally
accepted reiterative process of forward and back translations and
review by a survey research expert and local study users for 
the following languages: Afrikaans (South Africa), Chinese
(Taiwan), English (Canada), English (South Africa), English
(USA), French (Canada), Korean (Korea), Spanish (Mexico),
Swedish (Sweden), and Turkish (Turkey). All translators were
native speakers of the target language and ﬂuent in English (UK).
A diverse sample of 5 subjects in each language reviewed the har-
monized translations and was subsequently debriefed by trained
bilingual interviewers, ﬂuent in both English (UK) and the target
language. A team consisting of the original translators, back
